

CITATION REPORT

List of articles citing

Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction

DOI: 10.1111/j.1743-6109.2005.00194.x

Journal of Sexual Medicine, 2006, 3, 12-27.

Source: <https://exaly.com/paper-pdf/40748662/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
63	Sildenafil Associated Pupil-Sparing Third Nerve Palsy. <i>Neuro-Ophthalmology</i> , 2006 , 30, 117-119	0.9	2
62	Viagra and vision loss: what is known and unknown. <i>Clinical Nurse Specialist</i> , 2006 , 20, 227-8	0.6	3
61	Current awareness: Pharmacoepidemiology and drug safety. <i>Pharmacoepidemiology and Drug Safety</i> , 2006 , 15, i-xii	2.6	
60	Response to Tomsak, R. PDE5 inhibitors and permanent visual loss (Int J Impot Res 2005; 17: 547-549). <i>International Journal of Impotence Research</i> , 2006 , 18, 411; author reply 412	2.3	
59	Sildenafil citrate (Viagra) treatment for erectile dysfunction: An updated profile of response and effectiveness. <i>International Journal of Impotence Research</i> , 2006 , 18, 423-31	2.3	26
58	The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. <i>International Journal of Impotence Research</i> , 2007 , 19, 139-48	2.3	45
57	An overview on the toxic morphological changes in the retinal pigment epithelium after systemic compound administration. <i>Toxicologic Pathology</i> , 2007 , 35, 252-67	2.1	54
56	Sildenafil in the treatment of erectile dysfunction. <i>Aging Health</i> , 2007 , 3, 295-303		2
55	Sildenafil accelerates reentrainment of circadian rhythms after advancing light schedules. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 9834-9	11.5	49
54	Gene and stem cell therapy in the treatment of erectile dysfunction and pulmonary hypertension; potential treatments for the common problem of endothelial dysfunction. <i>Current Gene Therapy</i> , 2007 , 7, 131-53	4.3	9
53	Bilateral serous macular detachment in a woman on sildenafil for pulmonary hypertension. <i>Retinal Cases and Brief Reports</i> , 2007 , 1, 274-6	1.1	3
52	Viagra, surgery and anesthesia: a dangerous cocktail with a risk of blindness. <i>Medical Hypotheses</i> , 2007 , 68, 880-2	3.8	10
51	Visual loss associated with erectile dysfunction drugs. <i>Canadian Journal of Ophthalmology</i> , 2007 , 42, 10-12	1.4	
50	Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors. <i>International Journal of Clinical Practice</i> , 2007 , 61, 1547-54	2.9	20
49	The Journal of Sexual Medicine in 2007: the electronic age. <i>Journal of Sexual Medicine</i> , 2007 , 4, 1-3	1.1	
48	The effects of the phosphodiesterase type V inhibitor sildenafil on human and bovine retinal function in vitro. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , 2007 , 245, 1211-5	3.8	7
47	Phosphodiesterase type 5 inhibitors, visual changes, and nonarteritic anterior ischemic optic neuropathy: is there a link?. <i>Current Urology Reports</i> , 2007 , 8, 482-90	2.9	6

46	Expression of the PDE5 enzyme on human retinal tissue: new aspects of PDE5 inhibitors ocular side effects. <i>Eye</i> , 2008 , 22, 144-9	4.4	49
45	British Society for Sexual Medicine guidelines on the management of erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2008 , 5, 1841-65	1.1	98
44	Drug-induced ocular side effects. 2008 , 45-287		
43	Role of sildenafil in neurological disorders. <i>Clinical Neuropharmacology</i> , 2008 , 31, 353-62	1.4	36
42	A multicenter, randomized, open-labeled, parallel group trial of sildenafil in alcohol-associated erectile dysfunction: the impact on psychosocial outcomes. <i>International Journal of Environmental Research and Public Health</i> , 2009 , 6, 2510-25	4.6	3
41	[Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily Tadalafil]. <i>Der Urologe</i> , 2009 , 48, 1318, 1320-9		7
40	Structural basis of phosphodiesterase 6 inhibition by the C-terminal region of the gamma-subunit. <i>EMBO Journal</i> , 2009 , 28, 3613-22	13	49
39	Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. <i>International Journal of Clinical Practice</i> , 2010 , 64, 240-55	2.9	119
38	Drugs acting on the cerebral and peripheral circulations. <i>Side Effects of Drugs Annual</i> , 2009 , 31, 345-348	0.2	
37	Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date. <i>Drug Safety</i> , 2009 , 32, 1-18	5.1	57
36	Safety and quality assessment of 175 illegal sexual enhancement products seized in red-light districts in Singapore. <i>Drug Safety</i> , 2009 , 32, 1141-6	5.1	52
35	Sildenafil improves scotoma after posterior cerebral infarctions: a case report. <i>Journal of Neurology</i> , 2010 , 257, 674-7	5.5	2
34	Pharmacotherapy for erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2010 , 7, 524-40	1.1	132
33	Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 1427-37	5.9	61
32	Ocular findings of oral sildenafil use in term and near-term neonates. <i>Journal of AAPOS</i> , 2010 , 14, 159-62	1.3	22
31	Focus on phosphodiesterase inhibitors for the treatment of erectile dysfunction in older men. <i>Clinical Therapeutics</i> , 2011 , 33, 1590-608	3.5	10
30	Identification of amino acid residues responsible for the selectivity of tadalafil binding to two closely related phosphodiesterases, PDE5 and PDE6. <i>Journal of Biological Chemistry</i> , 2012 , 287, 41406-16	5.4	26
29	Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randomised, double masked, placebo controlled trial and open label extension. <i>BMJ, The</i> , 2012 , 344, e554	5.9	34

28	Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 1481-94	4	15
27	Ocular toxicity from systemically administered xenobiotics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012 , 8, 1277-91	5.5	27
26	Chronic low dosing of phosphodiesterase type 5 inhibitor for erectile dysfunction. <i>Korean Journal of Urology</i> , 2012 , 53, 377-85		8
25	ADMET considerations for phosphodiesterase-5 inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012 , 8, 1231-45	5.5	12
24	Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013 , 9, 1193-205	5.5	19
23	Does therapeutic dose of sildenafil citrate treatment lead to central serous chorioretinopathy in patients with erectile dysfunction?. <i>American Journal of Men's Health</i> , 2013 , 7, 439-43	2.2	10
22	The effect of sildenafil on retinopathy of prematurity in very preterm infants. <i>Journal of Perinatology</i> , 2013 , 33, 218-21	3.1	17
21	Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility. <i>Therapeutics and Clinical Risk Management</i> , 2014 , 10, 701-11	2.9	13
20	Iatrogenic neurology. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2014 , 121, 1635-71	3	0
19	Sildenafil alters retinal function in mouse carriers of retinitis pigmentosa. <i>Experimental Eye Research</i> , 2014 , 128, 43-56	3.7	23
18	Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors. <i>Journal of Sexual Medicine</i> , 2015 , 12, 139-51	1.1	52
17	Adverse drug reactions. <i>BMJ, The</i> , 2018 , 363, k4051	5.9	8
16	Unilateral transient cyanopsia as an early symptom of compressive optic neuropathy. <i>Neurological Sciences</i> , 2018 , 39, 2221-2222	3.5	
15	An update on the drug safety of treating erectile dysfunction. <i>Expert Opinion on Drug Safety</i> , 2019 , 18, 965-975	4.1	6
14	Sildenafil/Viagra in the treatment of premature ejaculation. <i>International Journal of Impotence Research</i> , 2019 , 31, 65-70	2.3	16
13	Catalytic Domains of Phosphodiesterase 5, 6, and 5/6 Chimera Display Differential Dynamics and Ligand Dissociation Energy Barriers. <i>Journal of Physical Chemistry B</i> , 2019 , 123, 825-835	3.4	4
12	Ethionamide induced blue vision (cyanopsia): Case report. <i>Indian Journal of Tuberculosis</i> , 2020 , 67, 333-335		2
11	Therapeutic Strategies for Erectile Dysfunction With Emphasis on Recent Approaches in Nanomedicine. <i>IEEE Transactions on Nanobioscience</i> , 2020 , 19, 11-24	3.4	1

10	Erectile dysfunction and retinal microvascular network: an optical coherence tomography angiography study. <i>International Journal of Impotence Research</i> , 2021 , 33, 318-324	2.3	4
9	Hormones and Drugs Affecting Hormonal Mechanisms. 2021 , 241-264		
8	Central Retinal Artery Occlusion Associated with Sildenafil Overdose. <i>Case Reports in Ophthalmological Medicine</i> , 2021 , 2021, 2006271	0.7	1
7	Ophthalmic Toxicology.		1
6	Erectile Dysfunction: Pharmacological Therapy. 2011 , 675-696		1
5	Drug-induced ocular side effects. 2015 , 47-343		
4	Phosphodiesterase type V inhibitors. 2016 , 734-742		
3	Retinal vein occlusion after intake of sildenafil citrate. <i>Regional Blood Circulation and Microcirculation</i> , 2017 , 16, 70-74	0.3	
2	Intraocular Hemorrhage due to use of Sildenafil in a Patient with Diabetes. <i>Medical Hypothesis, Discovery, and Innovation in Ophthalmology</i> , 2018 , 7, 122-125	1.4	2
1	Case report: Bilateral central serous chorioretinopathy-like abnormalities in a man with pulmonary arterial hypertension. 9,		